Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 6, 2010, Pages 2897-2901

  Ertugrul, Derun Taner ^a   Tutal, Emre ^a   Yildiz, Mehmet ^a   Akin, Okhan ^a   Yalçin, Ahmet Arif ^a   Üre, Öznur Sari ^a   Yilmaz, Hamiyet ^b   Yavuz, Bünyamin ^a   Deveci, Onur Sinan ^a   Ata, Naim ^a   Küçükazman, Metin ^a  

^a Kecioren Research and Training Hospital ^*  (Turkey)

^b Aydin State Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; URIC ACID; ANTITHROMBOCYTIC AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC CARDIOMYOPATHY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPEDANCE PLATELET AGGREGOMETRY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING; THROMBOCYTE AGGREGATION; ADULT; BLOOD; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG RESISTANCE; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK; STATISTICAL MODEL;

ADULT; ALANINE TRANSAMINASE; ASPIRIN; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, LDL; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LOGISTIC MODELS; MALE; OBESITY; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 77954471043     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2392     Document Type: Article

References (17)

1. Angiolillo DJ 2009 Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 32:531-540
2. Patrono C, García Rodriguez LA, Landolfi R, Baigent C 2005 Lowdose aspirin for the prevention of atherothrombosis. N Engl J Med 353:2373-2383
3. Angiolillo DJ 2009 Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 103(Suppl 3):27A-34A
4. Davì G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C 1997 Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96:69-75
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C 2005 Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430-2435
6. 2009 Executive Summary: Standards of Medical Care in Diabetes - 2009. Diabetes Care 32(Suppl 1):S6-S12
7. Carr ME 2001 Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 15:44-54
8. Cohen HW, Crandall JP, Hailpern SM, Billett HH 2008 Aspirin resistance associated with HbA1c and obesity in diabetic patients. J Diabetes Complications 22:224-228
9. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J 2004 Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 113:101-113
10. Fateh-Moghadam S, Plöckinger U, Cabeza N, Htun P, Reuter T, Ersel S, Gawaz M, Dietz R, Bocksch W 2005 Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99-103
11. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB 2006 Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567-570
12. Valles J, Santos MT, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Aznar J 1993 Downregulation of human platelet reactivity by neutrophils. J Clin Invest 92:1357-1365
13. Harrison P 2005 Platelet function analysis. Blood Rev 19:111-123
14. Cardinal DC, Flower RJ 1980 The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Methods 3:135-158
15. Jarvis GE 2004 Platelet aggregation in whole blood. Methods Mol Biol 272:77-87
16. Can MM, Tanboǧa IH, Türkyilmaz E, Karabay CY, Akgun T, Koca F, Tokgoz HC, Keles N, Ozkan A, Bezgin T, Ozveren O, Sonmez K, Saǧlam M, Ozdemir N, Kaymaz C The risk of false results in the assessment of platelet function in the absence of antiplatelet medication: comparison of the PFA-100, multiplate electrical impedance aggregometry and verify now assays. Thromb Res doi:10.1016/j.thromres.2009.11.005
17. Angiolillo DJ 2007 Antiplatelet therapy in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 14:124-131